<<
BACK TO SEVENTH GAVI BOARD MEETING
Seventh GAVI Board Meeting, Stockholm, 11 March 2002
4. Guidelines for use of Window #3 of the Vaccine
Fund
Click here
to download paper [MS Word, 77kb]
Discussion
- The GAVI research agenda needs to be focused on
implementation: what kind of research is required to get more
vaccines to more children in the shortest time?
- As we advocate for the development of new vaccines
it will be important to consider how vaccine standards have changed
– even in the last 20 years – and whether today’s regulatory hurdles
are too high to encourage new product development. This may warrant
further exploration and discussion at a future meeting.
- The involvement of developing country researchers
and manufacturers is essential in the GAVI research agendas.
DECISIONS
The Board:
4.1. Took note of the proposal to establish Accelerated
Development and Introduction Plans (ADIPs) to better address GAVI
priorities to speed development and introduction of pneumococcal
and rotavirus vaccines, and new technologies and management strategies
to improve immunization coverage. The meningococal vaccine is not
included as this project is already managed through the Meningococcal
Vaccine Program (MVP).
4.2. Requested more in-depth information on the management
structure and arrangements for accountability for the proposed ADIPs,
and on the selection process for the ADIP managers.
4.3. Agreed that more work needs to be done to elucidate
the ADIP process, particularly for managing R&D work once it
has been commissioned, how developing countries will be involved,
and how it will incorporate the efforts of all of the relevant GAVI
task forces, before guidelines for using Vaccine Fund resources
for R&D can be approved.
4.4. Will review the ADIPs for the pneumococcal and
rotavirus vaccines at its next Board meeting in June and consider
the need for opening Window 3 of the Vaccine Fund to support the
implementation of these plans.
<<
BACK TO SEVENTH GAVI BOARD MEETING
|